Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month zilver PTX randomized study results

Circulation: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 495-504

  Dake, Michael D ^a   Ansel, Gary M ^b   Jaff, Michael R ^c   Ohki, Takao ^d   Saxon, Richard R ^e   Smouse, H Bob ^f   Zeller, Thomas ^h   Roubin, Gary S ⁱ   Burket, Mark W ^j   Khatib, Yazan ^k   Snyder, Scott A ^l   Ragheb, Anthony O ^l   White, J King ^m   Machan, Lindsay S ^g  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MidWest Cardiology Research Foundation   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JIKEI UNIVERSITY HOSPITAL   (Japan)

^e Tri City Medical Center   (United States)

^f OSF SAINT FRANCIS MEDICAL CENTER   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

ⁱ LENOX HILL HOSPITAL   (United States)

^j UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^k PA   (United States)

^l Med Institute Inc Lafayette   (United States)

^m St Patrick Hospital   (United States)

more..

Author keywords

Angioplasty; Drug eluting stent; Paclitaxel eluting stent; Peripheral vascular disease

Indexed keywords

NITINOL; PACLITAXEL; POLYMER;

AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FEMOROPOPLITEAL PERIPHERAL ARTERY DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; BLOOD VESSEL PROSTHESIS IMPLANTATION; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 82955173056     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.962324     Document Type: Article

References (32)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45: S5A-S67A.
2. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Cath Cardiovasc Interv. 2007;69:910-919. (Pubitemid 46867500)
3. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888. (Pubitemid 43872689)
4. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37:487-494. (Pubitemid 36350887)
5. Grimm J, Muller-Hülsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001; 12:935-942.
6. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116: 285-292. (Pubitemid 47196564)
7. Bosiers M, Torsello G, Gissler HM, Ruef J, Muller-Hülsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroë H, Mathias K, Koppensteiner R, Vermassen F, Scheinert D. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of DURABILITY I study. J Endovasc Ther. 2009;16:261-269.
8. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
9. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with slow-release, polymer-based, paclitaxeleluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109: 1942-1947. (Pubitemid 38544483)
10. Fajadet J, Morice MC, Bode C, Barragan P, Serruys P, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-1044. (Pubitemid 40354523)
11. Gershlick A, Scheerder ID, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel eluting (ELUTES) trial. Circulation. 2004;109:487-493. (Pubitemid 38168511)
12. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348: 1537-1545. (Pubitemid 36437930)
13. Duda SH, Bosiers M, Lammers J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710. (Pubitemid 44907633)
14. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol selfexpanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394-401.
15. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645. (Pubitemid 27329445)
16. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879-884. (Pubitemid 30246985)
17. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101: 9463-9467. (Pubitemid 38812897)
18. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699. (Pubitemid 351240748)
19. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
20. Hiatt WR, Hirsh AT, Regensteiner JG, Brass EP. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Circulation. 1995;92:614-621.
21. Mewissen MW. Nitinol stents in the femoropopliteal arterial segment. Endovasc Today. 2003;2:29-34.
22. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, Lammer J. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31. (Pubitemid 32097991)
23. Deutschmann HA, Schedlbauer P, Bérczi V, Portugaller H, Tauss J, Hausegger KA. Placement of Hemobahn stent-grafts in femoropopliteal arteries: early experience and midterm results in 18 patients. J Vasc Interv Radiol. 2001;12:943-950.
24. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology. 2002;222:37-43. (Pubitemid 34031461)
25. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC working group: TransAtlantic Inter-Society Consensus (TASC) J Vasc Surg. 2000;31(1 Part 2):S1-S296.
26. Silver MJ, Ansel GM. Femoropopliteal occlusive disease: diagnosis, indications for treatment and results of interventional therapy. Cathet Cardiovasc Intervent. 2002;56:555-561. (Pubitemid 34809042)
27. O'Brien R, Castelloe J. Sample-size analysis in study planning. ASA Continuing Education Program, Joint Statistical Meetings, San Francisco, August 2003.
28. Jaff M, Dake M, Popma J, Ansel G, Yoder T. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Cathet Cardiovasc Intervent. 2007;70:460-462. (Pubitemid 350194998)
29. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697. (Pubitemid 26320276)
30. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. (Pubitemid 38222887)
31. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
32. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315. (Pubitemid 40094743)